检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:唐炜[1] 叶熹罡[1] 高进[1] 陈伦[1] 潘凌霄[1] 郑文博[1]
机构地区:[1]广州医学院第一附属医院乳腺外科,广东广州510120
出 处:《广州医学院学报》2013年第2期33-37,共5页Academic Journal of Guangzhou Medical College
基 金:广东省科技计划项目(2010B060900094)
摘 要:目的:探讨miRNA-21(miR-21)和其靶基因程序性细胞死亡4(programmed cell death 4,PDCD4)在乳腺癌的表达及与预后的关系。方法:运用实时定量PCR检测87例乳腺浸润性导管癌组织miR-21和PDCD4的表达,并对生存时间进行分析。结果:miR-21与PDDCD4的表达呈负相关,相关系数r_s=-0.631(P<0.01);在远处转移组中miR-21的表达高于非远处转移组(P<0.001),PDCD4则低于非远处转移组(P<0.001);两者表达均与肿瘤组织学分级、肿瘤大小、淋巴结及远处转移情况相关(P<0.05)。miR-21高表达组和PDCD4低表达组患者有较长的无病生存期(DFS)和总生存期(OS)(P<0.05)。结论:乳腺癌组织中miR-21高表达与PDCD4低表达与乳腺癌预后相关,可作为乳腺癌恶性程度的预测指标。Objective:To investigate the miR-21 and programmed cell death 4 (PDCD4) expressions and their association with prognosis of breast cancer. Methods: The infiltrating ductal adenocarcinoma tissues obtained from 87 patients with breast cancer admitted to The First Affiliated Hospital of Guangzhou Medical College for surgical resection between June 2008 and August 2011 were subjected to miR-21 and PDCD4 expression via real-time reverse transcriptase polymerase chain reaction. This entailed further analysis on the survival time. Results: The miR-21 expression was inversely correlated with PDCD4 expression (r = -0. 631, P 〈 0. 01 ). Patients with distal metastasis yielded an augmented miR-21 expression yet attenuated PDCD4 expression than those without ( both P 〈 0. 001 ). The miR-21 and PDCD4 expressions were correlated with pathological stage, size of tumor, lymph node or distal metastasis ( all P 〈0.05). High miR-21 expression and low PDCD4 expression were associated with prolonged disease-free survival or overall survival ( both P 〈 0.05). Conclusion: High miR-21 expression and low PDCD4 expression are associated with poor prognosis and may serve as an independent prognostic marker of breast cancer.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.229